| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.33.5208 |
| P698 | PubMed publication ID | 21859991 |
| P50 | author | Hani Gabra | Q5648162 |
| Gordon C. Jayson | Q37839060 | ||
| Timothy Perren | Q43194270 | ||
| Iain A McNeish | Q55130375 | ||
| Helena Earl | Q55477671 | ||
| P2093 | author name string | Martin Gore | |
| Malcolm Adams | |||
| Allan Hackshaw | |||
| Jonathan A Ledermann | |||
| Graham Temple | |||
| Stan Kaye | |||
| Michael Merger | |||
| Gordon Rustin | |||
| Mojca Persic | |||
| Lindsay James | |||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| placebo | Q269829 | ||
| chemotherapy | Q974135 | ||
| phase II clinical trial | Q42824440 | ||
| placebo-controlled trial | Q108853737 | ||
| P304 | page(s) | 3798-3804 | |
| P577 | publication date | 2011-08-22 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer | |
| P478 | volume | 29 |
| Q89057719 | A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma |
| Q43902249 | A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia |
| Q100736351 | A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer |
| Q52628568 | A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. |
| Q38553247 | An overview of early investigational therapies for chemoresistant ovarian cancer. |
| Q38631373 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. |
| Q55217694 | Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. |
| Q38130312 | Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales |
| Q38115596 | Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment |
| Q35205410 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. |
| Q58706801 | Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials |
| Q37661852 | Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis |
| Q33662162 | Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review |
| Q26779120 | Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer |
| Q38151193 | Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer |
| Q27024235 | Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer |
| Q37937858 | Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer |
| Q38286128 | Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy |
| Q43657215 | Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study |
| Q36855239 | Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer |
| Q90133145 | Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity |
| Q37981986 | FGF receptor inhibitors: role in cancer therapy |
| Q37462489 | FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. |
| Q38213500 | First-line and maintenance therapy for ovarian cancer: current status and future directions |
| Q37512962 | Focus on Nintedanib in NSCLC and Other Tumors |
| Q38123207 | Genetic changes in nonepithelial ovarian cancer |
| Q33598883 | Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray |
| Q38169470 | Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications |
| Q33563488 | Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib |
| Q92451281 | Inhibitory effect of nintedanib on VEGF secretion in retinal pigment epithelial cells induced by exposure to a necrotic cell lysate |
| Q33920800 | Investigational agents in development for the treatment of ovarian cancer |
| Q38340008 | Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. |
| Q90231859 | Kinase Inhibitors and Ovarian Cancer |
| Q65000120 | Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review. |
| Q26781561 | Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis |
| Q38222277 | Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents |
| Q93059467 | Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study |
| Q42347314 | Negative trials in ovarian cancer: is there such a thing as too much optimism? |
| Q38175506 | New biological treatments for gynecological tumors: focus on angiogenesis |
| Q28082524 | New perspectives on targeted therapy in ovarian cancer |
| Q51824301 | Nintedanib in ovarian cancer. |
| Q64284104 | Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition |
| Q35670576 | Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. |
| Q38430583 | Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology |
| Q54307476 | Nintedanib: first global approval. |
| Q47424260 | Novel antiangiogenic therapies in ovarian cancer |
| Q38198095 | Novel therapies, including enzastaurin, in the treatment of ovarian cancer |
| Q38654552 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial |
| Q26777846 | Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge |
| Q54105461 | Ovarian cancer |
| Q38040628 | Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. |
| Q37332480 | Ovarian cancer: genomic analysis. |
| Q38180762 | PARP inhibitors for anticancer therapy |
| Q35602123 | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute |
| Q36648394 | Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
| Q26777928 | Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine |
| Q64237473 | Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors |
| Q35678397 | Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). |
| Q35623311 | Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. |
| Q41130079 | Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer |
| Q35739542 | Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours |
| Q43989660 | Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme |
| Q37996468 | Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages |
| Q36730777 | Prediction of anti-angiogenesis escape |
| Q47664784 | Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck |
| Q26751280 | Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives |
| Q26775134 | Profile of nintedanib in the treatment of solid tumors: the evidence to date |
| Q37390113 | Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. |
| Q51795514 | Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. |
| Q36957621 | Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib |
| Q37495153 | Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume. |
| Q27016629 | Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies |
| Q30249619 | Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis. |
| Q47719824 | Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer |
| Q83840457 | Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer |
| Q33427744 | Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q38760610 | Targeted agents and combinations in ovarian cancer: where are we now? |
| Q26750649 | Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments |
| Q26830287 | Targeted anti-vascular therapies for ovarian cancer: current evidence |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q95383069 | Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment |
| Q37988981 | Targeted therapy in head and neck cancer |
| Q26824766 | Targeting angiogenesis in gynecologic cancers |
| Q58789499 | Targeting the Microenvironment in High Grade Serous Ovarian Cancer |
| Q36626921 | Targeting the tumour microenvironment in ovarian cancer |
| Q38118388 | Targeting tyrosine-kinases in ovarian cancer |
| Q27698320 | The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition |
| Q30248645 | The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review |
| Q38144166 | The potential of sunitinib as a therapy in ovarian cancer |
| Q35920527 | The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis |
| Q39393740 | Tumor angiogenesis revisited: Regulators and clinical implications. |
| Q36571743 | Update on first-line treatment of advanced ovarian carcinoma |
| Q36929772 | Updates on drug discovery in ovarian cancer |
| Q33926377 | Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis |
Search more.